FDA rejects Osteal combo therapy to treat joint-implant infections

FDA rejects Osteal Therapeutics' Nexchange Kit antibiotic combo for joint-implant infections, citing trial-design flaws and fungal PJI risk.

Raccontata daendpoints.news